399 related articles for article (PubMed ID: 18400502)
1. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 May; 16(10):5795-802. PubMed ID: 18400502
[TBL] [Abstract][Full Text] [Related]
2. Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme.
Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 Jul; 16(14):6880-90. PubMed ID: 18558491
[TBL] [Abstract][Full Text] [Related]
3. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors.
Nguyen JT; Zhang M; Kumada HO; Itami A; Nishiyama K; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2008 Jan; 18(1):366-70. PubMed ID: 18006315
[TBL] [Abstract][Full Text] [Related]
4. Maintaining potent HTLV-I protease inhibition without the P3-cap moiety in small tetrapeptidic inhibitors.
Nguyen JT; Kato K; Kumada HO; Hidaka K; Kimura T; Kiso Y
Bioorg Med Chem Lett; 2011 Mar; 21(6):1832-7. PubMed ID: 21316958
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles.
Nguyen JT; Kato K; Hidaka K; Kumada HO; Kimura T; Kiso Y
Bioorg Med Chem Lett; 2011 Apr; 21(8):2425-9. PubMed ID: 21392990
[TBL] [Abstract][Full Text] [Related]
6. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
[TBL] [Abstract][Full Text] [Related]
7. Substrates and inhibitors of human T-cell leukemia virus type I protease.
Ding YS; Rich DH; Ikeda RA
Biochemistry; 1998 Dec; 37(50):17514-8. PubMed ID: 9860866
[TBL] [Abstract][Full Text] [Related]
8. Chipping at large, potent human T-cell leukemia virus type 1 protease inhibitors to uncover smaller, equipotent inhibitors.
Kimura T; Nguyen JT; Maegawa H; Nishiyama K; Arii Y; Matsui Y; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2007 Jun; 17(12):3276-80. PubMed ID: 17448657
[TBL] [Abstract][Full Text] [Related]
9. Development of [Ile⁴⁰]HTLV-I protease inhibition assay using novel fluorogenic and chromogenic substrate.
Kumada HO; Nguyen JT; Kakizawa T; Hidaka K; Kimura T; Hayashi Y; Kiso Y
J Pept Sci; 2011 Aug; 17(8):569-75. PubMed ID: 21574213
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability.
Kimura T; Shuto D; Hamada Y; Igawa N; Kasai S; Liu P; Hidaka K; Hamada T; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2005 Jan; 15(1):211-5. PubMed ID: 15582441
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of retro-inverso modifications of HTLV-1 protease inhibitors containing a hydroxyethylamine isoster.
Tatsumi T; Awahara C; Naka H; Aimoto S; Konno H; Nosaka K; Akaji K
Bioorg Med Chem; 2010 Apr; 18(7):2720-7. PubMed ID: 20226680
[TBL] [Abstract][Full Text] [Related]
12. Design of potent aspartic protease inhibitors to treat various diseases.
Nguyen JT; Hamada Y; Kimura T; Kiso Y
Arch Pharm (Weinheim); 2008 Sep; 341(9):523-35. PubMed ID: 18763714
[TBL] [Abstract][Full Text] [Related]
13. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
[TBL] [Abstract][Full Text] [Related]
14. Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.
Blum A; Böttcher J; Sammet B; Luksch T; Heine A; Klebe G; Diederich WE
Bioorg Med Chem; 2008 Sep; 16(18):8574-86. PubMed ID: 18760609
[TBL] [Abstract][Full Text] [Related]
15. Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
Maegawa H; Kimura T; Arii Y; Matsui Y; Kasai S; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2004 Dec; 14(23):5925-9. PubMed ID: 15501070
[TBL] [Abstract][Full Text] [Related]
16. Evaluations of substrate specificity and inhibition at PR/p3 cleavage site of HTLV-1 protease.
Naka H; Teruya K; Bang JK; Aimoto S; Tatsumi T; Konno H; Nosaka K; Akaji K
Bioorg Med Chem Lett; 2006 Jul; 16(14):3761-4. PubMed ID: 16682197
[TBL] [Abstract][Full Text] [Related]
17. Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells.
Demir A; Oguariri RM; Magis A; Ostrov DA; Imamichi T; Dunn BM
Antivir Ther; 2012; 17(5):883-92. PubMed ID: 22436331
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
[TBL] [Abstract][Full Text] [Related]
19. Substrates and inhibitors of human T-cell leukemia virus type 1 (HTLV-1) proteinase.
Hrusková-Heidingsfeldová O; Bláha I; Urban J; Strop P; Pichová I
Leukemia; 1997 Apr; 11 Suppl 3():45-6. PubMed ID: 9209292
[TBL] [Abstract][Full Text] [Related]
20. Achiral, cheap, and potent inhibitors of Plasmepsins I, II, and IV.
Boss C; Corminboeuf O; Grisostomi C; Meyer S; Jones AF; Prade L; Binkert C; Fischli W; Weller T; Bur D
ChemMedChem; 2006 Dec; 1(12):1341-5. PubMed ID: 17091526
[No Abstract] [Full Text] [Related]
[Next] [New Search]
